AbbVie Inc.

NYSE:ABBV Stock Report

Market Cap: US$394.7b

AbbVie Valuation

Is ABBV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ABBV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ABBV ($227.45) is trading below our estimate of fair value ($418.43)

Significantly Below Fair Value: ABBV is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ABBV?

Key metric: As ABBV is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ABBV. This is calculated by dividing ABBV's market cap by their current revenue.
What is ABBV's PS Ratio?
PS Ratio6.7x
SalesUS$59.64b
Market CapUS$394.69b

Price to Sales Ratio vs Peers

How does ABBV's PS Ratio compare to its peers?

The above table shows the PS ratio for ABBV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.3x
GILD Gilead Sciences
5.1x3.78%US$149.4b
AMGN Amgen
4.8x2.19%US$171.1b
VRTX Vertex Pharmaceuticals
9.8x9.13%US$114.7b
REGN Regeneron Pharmaceuticals
5.3x7.20%US$76.1b
ABBV AbbVie
6.7x7.30%US$394.7b

Price-To-Sales vs Peers: ABBV is expensive based on its Price-To-Sales Ratio (6.7x) compared to the peer average (6.3x).

Price to Sales Ratio vs Industry

How does ABBV's PS Ratio compare vs other companies in the US Biotechs Industry?

140 CompaniesPrice / SalesEstimated GrowthMarket Cap
AMGN Amgen
4.8x2.19%US$171.10b
BIIB Biogen
2.5x-1.75%US$25.54b
INCY Incyte
3.9x2.19%US$18.73b
EXEL Exelixis
4.9x10.36%US$11.00b
ABBV 6.7xIndustry Avg. 12.1xNo. of Companies140PS020406080100+
140 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: ABBV is good value based on its Price-To-Sales Ratio (6.7x) compared to the US Biotechs industry average (12.1x).

Price to Sales Ratio vs Fair Ratio

What is ABBV's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ABBV PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6.7x
Fair PS Ratio11.2x

Price-To-Sales vs Fair Ratio: ABBV is good value based on its Price-To-Sales Ratio (6.7x) compared to the estimated Fair Price-To-Sales Ratio (11.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ABBV forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$223.32
US$244.29
+9.39%
10.53%US$289.00US$184.00n/a28
Dec ’26US$225.11
US$243.55
+8.19%
10.27%US$289.00US$184.00n/a29
Nov ’26US$218.04
US$237.37
+8.87%
11.20%US$284.00US$184.00n/a27
Oct ’26US$244.38
US$227.78
-6.79%
9.07%US$270.00US$184.00n/a27
Sep ’26US$210.40
US$216.48
+2.89%
9.96%US$255.00US$170.00n/a27
Aug ’26US$195.22
US$213.12
+9.17%
10.29%US$255.00US$170.00n/a26
Jul ’26US$189.99
US$209.12
+10.07%
10.03%US$250.00US$170.00n/a27
Jun ’26US$186.11
US$209.61
+12.63%
9.87%US$250.00US$170.00n/a27
May ’26US$193.34
US$210.68
+8.97%
9.21%US$250.00US$173.00n/a27
Apr ’26US$206.27
US$211.73
+2.65%
9.14%US$250.00US$173.00n/a25
Mar ’26US$209.03
US$205.75
-1.57%
8.87%US$239.00US$165.00n/a26
Feb ’26US$183.90
US$203.34
+10.57%
8.70%US$239.00US$165.00n/a27
Jan ’26US$177.70
US$202.54
+13.98%
8.90%US$240.00US$165.00n/a28
Dec ’25US$182.93
US$204.48
+11.78%
8.15%US$240.00US$165.00US$225.1128
Nov ’25US$203.55
US$207.80
+2.09%
7.84%US$240.00US$170.00US$218.0428
Oct ’25US$196.96
US$196.54
-0.21%
6.99%US$218.00US$170.00US$244.3826
Sep ’25US$196.31
US$196.30
-0.0045%
6.90%US$218.00US$170.00US$210.4027
Aug ’25US$189.71
US$194.23
+2.38%
7.03%US$215.00US$170.00US$195.2227
Jul ’25US$170.37
US$183.67
+7.81%
5.67%US$207.00US$168.00US$189.9927
Jun ’25US$161.24
US$182.60
+13.25%
6.12%US$207.00US$161.00US$186.1127
May ’25US$161.72
US$183.11
+13.22%
5.81%US$206.00US$161.00US$193.3427
Apr ’25US$180.76
US$183.88
+1.73%
6.28%US$206.00US$161.00US$206.2727
Mar ’25US$178.91
US$180.74
+1.02%
7.20%US$206.00US$153.00US$209.0326
Feb ’25US$167.59
US$172.42
+2.88%
9.42%US$205.00US$135.00US$183.9027
Jan ’25US$154.97
US$167.78
+8.27%
10.62%US$201.00US$126.00US$177.7028
Dec ’24US$143.41
US$167.35
+16.69%
10.57%US$201.00US$126.00US$182.9328
US$244.29
Fair Value
6.9% undervalued intrinsic discount
28
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/15 22:57
End of Day Share Price 2025/12/15 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AbbVie Inc. is covered by 53 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Luisa HectorBerenberg
Evan SeigermanBMO Capital Markets Equity Research